GENI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Genius Sports Ltd (GENI) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock's technical indicators show a lack of clear upward momentum, and the recent financial performance highlights significant challenges, including rising costs and declining net income. While hedge fund interest has increased, analyst ratings and price target adjustments reflect cautious sentiment due to uncertainties surrounding the Legend acquisition. The options data indicates low bearish sentiment, but this alone does not outweigh the broader concerns. For now, holding off on buying GENI until clearer positive catalysts emerge is advisable.
The MACD histogram is positive at 0.141, indicating mild bullish momentum, but it is contracting. RSI_6 at 36.025 is neutral, showing no clear overbought or oversold condition. Moving averages are converging, suggesting a lack of strong directional movement. Key support is at $5.709, and resistance is at $6.147. Overall, the technical indicators do not signal a strong buy opportunity.
Hedge funds are significantly increasing their positions, with a 266.25% increase in buying over the last quarter.
Revenue growth remains strong, with a 31% YoY increase in 2025 and a 37% increase in Q
The company reaffirmed its 2026 revenue guidance of $810-820 million, indicating confidence in future growth.
Rising costs and a quarterly net loss have pressured the stock, with Q4 GAAP EPS at -$0.
Analysts have significantly lowered price targets, reflecting concerns about the Legend acquisition and its strategic fit.
Gross margin dropped to 24.85%, down 25.49% YoY, indicating declining profitability.
Insider trading activity is neutral, showing no strong internal confidence in the stock.
In 2025, Genius Sports achieved a 31% revenue growth to $669 million and a record adjusted EBITDA margin of 20%. However, net income dropped significantly to -$28.81 million in Q3, down 330.42% YoY, and EPS fell to -0.11. Rising costs and the Legend acquisition have raised concerns about cash flow and profitability.
Analysts have lowered price targets across the board, with the latest targets ranging from $6 to $15. Despite some maintaining Buy or Overweight ratings, the sentiment is cautious due to uncertainties surrounding the Legend acquisition and its impact on the company's financials. UBS and Stifel have expressed concerns about cash flow and the strategic fit of the acquisition.
